Biostock interviews Chordate Medical’s Medical Director about new study

Biostock interviews Chordate Medical’s Medical Director Jan Hermansson about the company’s post-market study PM010, which was recently initiated.

“Since this is an open study, we will be able to analyse the results on an ongoing basis. When we have a sufficient number of patients who have been on treatment long enough, we will conduct interim analyses […] We have selected clinics with a higher patient flow that did not participate in 007. Recognizing the challenges of patient recruitment for studies, we sought clinics with a substantial pool of patients to choose from. Additionally, it has been crucial that both the clinic’s management and healthcare team express a clear interest in our drug-free treatment alternative”, says Jan Hermansson to Biostock.

Read the full interview

More posts

For questions about Chordate’s share price or other investment-related topics, please see if the answer is here.

For questions about the medical effects of Ozilia® Migraine, please see if the answer is here.

To get in touch with Chordate regarding other questions, use the adjecent form. We do our best to respond as quickly as possible.

Please note that the MAR rules (Market Abuse Regulation) prohibits us from providing information to individual inquirers regarding matters of the company’s share, share price, economy and financials, commercial and scientific activities, and other information that potentially can alter the Market valuation of the traded share. We refer in general to the public information published by the company for such questions. Hence, emails with such questions will not be responded to individually.

Contact us

  • This field is for validation purposes and should be left unchanged.

The information is handled according to our privacy policy